Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
Intervalo de año de publicación
1.
Zhongguo Ying Yong Sheng Li Xue Za Zhi ; 38(5): 406-411, 2022 Sep.
Artículo en Zh | MEDLINE | ID: mdl-37088742

RESUMEN

OBJECTIVE: In the present study, we determined whether the glycogen phosphorylase(GP)inhibitor 1,4-dideoxy-1,4-imino-D-arabinitol (DAB) ameliorates pentylenetetrazole (PTZ)-induced acute seizure, neuroinflammation and memory impairment in rats. METHODS: In experiment 1, rats were randomly divided into the Vehicle (n=5) and PTZ (n=5) groups, and received intraperitoneal injection of saline or PTZ (70 mg/kg), respectively. Hippocampal tissues were collected 30 min after drug injection. Western blot was used to examine the levels of GP expression. Colorimetric assay was used to determine the levels of lactate. In experiment 2, rats were randomly divided into the Vehicle+Vehicle (n=18), DAB+Vehicle (n=18), Vehicle+PTZ (n=19) and DAB+PTZ (n=18) groups. Rats received intracerebroventricular injection of PBS or DAB (50 µg/2 µl) 15 min before receiving intraperitoneal injection of saline or PTZ (70 mg/kg). Behavioural assays and the Racine scale were used to evaluate seizure severity. Western blot was used to examine the levels of targeted protein of hippocampal tissues. Novel object recognition test was used to assess memory performance. RESULTS: ① Compared with the Vehicle group, the levels of GP and lactate in the hippocampal tissues of the PTZ group were increased significantly (both P<0.01). ② Compared with the Vehicle+PTZ group, in the DAB+PTZ group, the levels of myoclonic body jerk latency, forelimb clonus latency and tonic-clonic seizure latency were increased significantly (all P<0.01), while the duration of seizure and seizure scores were decreased significantly (both P<0.01). ③ Compared with the Vehicle+Vehicle group, in the Vehicle +PTZ group, the levels of IL-1ß, IL-6, TNF-α, IBA-1 and GFAP in the hippocampal tissues were increased significantly (all P<0.01), and the discrimination index in the novel object recognition test was decreased significantly (P<0.01). Compared with the Vehicle+PTZ group, in the DAB+PTZ group, the levels of IL-1ß, TNF-α, IBA-1 and GFAP in the hippocampal tissues were decreased significantly (all, P<0.01), while the discrimination index in the novel object recognition test was increased significantly (P<0.01). CONCLUSION: DAB ameliorates PTZ-induced seizure, neuroinflammation and memory impairment in rats, suggesting that DAB may serve as a novel agent for potential clinical treatment of epilepsy.


Asunto(s)
Glucógeno Fosforilasa , Enfermedades Neuroinflamatorias , Convulsiones , Animales , Ratas , Anticonvulsivantes/efectos adversos , Anticonvulsivantes/uso terapéutico , Glucógeno Fosforilasa/antagonistas & inhibidores , Lactatos/efectos adversos , Enfermedades Neuroinflamatorias/tratamiento farmacológico , Pentilenotetrazol/efectos adversos , Convulsiones/inducido químicamente , Convulsiones/complicaciones , Factor de Necrosis Tumoral alfa
2.
Neuropeptides ; 87: 102131, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33640616

RESUMEN

Apelin is an endogenous ligand of G protein-coupled receptor APJ. In recent years, many studies have shown that the apelin/APJ system has neuroprotective properties, such as anti-inflammatory, anti-oxidative stress, anti-apoptosis, and regulating autophagy, blocking excitatory toxicity. Apelin/APJ system has been proven to play a role in various neurological diseases and may be a promising therapeutic target for nervous system diseases. In this paper, the neuroprotective properties of the apelin/APJ system and its role in neurologic disorders are reviewed. Further understanding of the pathophysiological effect and mechanism of the apelin/APJ system in the nervous system will help develop new therapeutic interventions for various neurological diseases.


Asunto(s)
Receptores de Apelina/fisiología , Apelina/fisiología , Enfermedades del Sistema Nervioso/fisiopatología , Animales , Apelina/uso terapéutico , Apoptosis/efectos de los fármacos , Autofagia/efectos de los fármacos , Lesiones Traumáticas del Encéfalo/tratamiento farmacológico , Lesiones Traumáticas del Encéfalo/fisiopatología , Epilepsia/tratamiento farmacológico , Epilepsia/fisiopatología , Humanos , Inflamación , Accidente Cerebrovascular Isquémico/tratamiento farmacológico , Accidente Cerebrovascular Isquémico/fisiopatología , Trastornos Mentales/tratamiento farmacológico , Trastornos Mentales/fisiopatología , Ratones , Modelos Neurológicos , Enfermedades Neurodegenerativas/tratamiento farmacológico , Enfermedades Neurodegenerativas/fisiopatología , Fármacos Neuroprotectores/uso terapéutico , Neurotoxinas/farmacología , Estrés Oxidativo/efectos de los fármacos , Manejo del Dolor , Fragmentos de Péptidos/farmacología , Fragmentos de Péptidos/uso terapéutico , Ratas , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA